hims and hers semaglutide Affordability Safety: How & is Delivering a New GLP-1 Experience Through the Scale of Our Platform Full Range of FDA-Approved GLP-1s

In most cases, weight loss resumes once the new medication reaches therapeutic levels and the body adapts to the different receptor activation pattern

HRT carries documented risks including blood clots, stroke, breast cancer, and endometrial cancer that are evaluated by the treating clinician based on individual patient profile

Some of this will be absorbed through the GI tract, though at much lower bioavailability

Protocol 1: moderate weight loss (10-15% body weight) Goal: Steady, sustainable weight loss with minimal side effects Tirzepatide approach: Standard escalation to 5-7.5 mg Hold at the dose where you achieve consistent weekly loss of 0.5-1% body weight Expected timeline: 24-36 weeks to target Likely maintenance dose: 5-7.5 mg Retatrutide approach: Standard escalation to 4 mg 4 mg delivered 12.9% weight loss at 24 weeks in trials Hold at 4 mg if achieving target rate Expected timeline: 20-30 weeks to target For moderate goals, both compounds work well at their lower dose ranges